NO20070521L - Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40 - Google Patents

Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40

Info

Publication number
NO20070521L
NO20070521L NO20070521A NO20070521A NO20070521L NO 20070521 L NO20070521 L NO 20070521L NO 20070521 A NO20070521 A NO 20070521A NO 20070521 A NO20070521 A NO 20070521A NO 20070521 L NO20070521 L NO 20070521L
Authority
NO
Norway
Prior art keywords
gpr40
single nucleotide
nucleotide polymorphism
coupled receptor
protein coupled
Prior art date
Application number
NO20070521A
Other languages
English (en)
Inventor
Poulabi Banerjee
Karen Lynne Houseknecht
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20070521L publication Critical patent/NO20070521L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Denne oppfinnelsen er relatert til fremgangsmåter av genotyping, fremgangsmåter for behandling, diagnostiske tester og fremgangsmåter for å karakterisere et middel, relatert til en enkel nukleotid polymorfisme av GPR40-genet.
NO20070521A 2004-06-30 2007-01-26 Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40 NO20070521L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58468604P 2004-06-30 2004-06-30
US11/046,020 US20060003344A1 (en) 2004-06-30 2005-01-28 Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
PCT/IB2005/001962 WO2006006062A1 (en) 2004-06-30 2005-06-20 Methods related to a single nucleotide polymorphism of the g protein coupled receptor, gpr40

Publications (1)

Publication Number Publication Date
NO20070521L true NO20070521L (no) 2007-01-26

Family

ID=35514424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070521A NO20070521L (no) 2004-06-30 2007-01-26 Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40

Country Status (10)

Country Link
US (1) US20060003344A1 (no)
EP (1) EP1763585A1 (no)
JP (1) JP2008504836A (no)
AU (1) AU2005261437A1 (no)
BR (1) BRPI0512745A (no)
CA (1) CA2570921A1 (no)
IL (1) IL179911A0 (no)
MX (1) MXPA06014024A (no)
NO (1) NO20070521L (no)
WO (1) WO2006006062A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EA011010B1 (ru) * 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
US7687526B2 (en) * 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2007293028B2 (en) * 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
JP2008195625A (ja) * 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
CA2683751C (en) * 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
US8450522B2 (en) * 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7214495B2 (en) * 2002-02-14 2007-05-08 Takeda Pharmaceutical Company Limited Screening method

Also Published As

Publication number Publication date
JP2008504836A (ja) 2008-02-21
BRPI0512745A (pt) 2008-04-08
US20060003344A1 (en) 2006-01-05
CA2570921A1 (en) 2006-01-19
MXPA06014024A (es) 2007-02-08
EP1763585A1 (en) 2007-03-21
IL179911A0 (en) 2007-05-15
WO2006006062A1 (en) 2006-01-19
AU2005261437A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
MX343863B (es) Conjunto de sondas de oligonucleotido y metodos para perfilado de microbiotica.
GB2457402B (en) Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
NO20083204L (no) Kombinasjon av en H3-antagonist/inversagonist og en appetittdemper
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2007149982A3 (en) Diagnosis of autoimmune disease
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
WO2008073895A3 (en) Methods and devices for testing saliva
NO20044628L (no) Immunglobulindomene som inneholder celleoverflategjenkjennende molekyler
BRPI0512745A (pt) métodos de genotipagem e de caracterizar um agente e kit
NO20073369L (no) Modulatorer av muskarinreseptorer
MX2007002908A (es) Sondas inmovilizadas y metodos para detectar proteinas prionicas alteradas conformacionalmente.
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
WO2008011484A3 (en) Nicotinic desensitizers and methods of selecting, testing, and using them
DE602004026785D1 (de) Chemische reaktionsvorrichtung unter pseudo-isothermischen bedingungen für heterogene chemische reaktionen
NO20082410L (no) Biomarkorer for anti-nogo-a antistoffbehandling ved spinalstrengskader
BRPI0520067A2 (pt) desenvolvimento de um ensaio de pcr em tempo real para a detecção de dna pneumocócico e diagnóstico da doença pneumocócica
ATE526585T1 (de) Natürlicher ligand des g-protein-gekoppelten rezeptors rcc356 und verwendungen davon
ATE490339T1 (de) Diagnostikum für osteoporose
NO20070780L (no) Celloverflateprotein.
DK1853721T3 (da) Fremgangsmåde til bestemmelse af reaktionsevne over for CHK1-inhibitorer
TW200801200A (en) Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application